The overlooked middle class of biopharma

Biopharma coverage often focuses on two parts of the industry: the largest global drugmakers and the smallest venture-backed biotech companies. Between them sits a broad group of mid-sized regional companies that play an important role in how medicines are developed, manufactured, licensed and commercialized.

These companies are not all the same. Some are specialty pharmaceutical groups with branded products and selective R&D. Some are generics and biosimilars manufacturers moving into higher-value products. Some are regional commercialization partners. Others combine manufacturing, in-licensing, local market access and limited innovation.